You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 101

    DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel method for inhibiting diabetic retinopathy

    SBC: CMP Tarnhelm Partners            Topic: N

    DESCRIPTION provided by applicant The long term objective of this project study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy Insulin like growth factor I IGF I has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease but IGF I concentrations in retina are not increased During hyperglycemia IGF I activa ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence

    SBC: CELLF-BIO LLC            Topic: 300

    DESCRIPTION provided by applicant We propose to bring to market a novel regenerative medicine based therapy for fecal incontinence FI FI is the recurrent uncontrolled passage of fecal material The Internal Anal Sphincter IAS is responsible for maintaining anorectal continence Function of the IAS is dependent upon the neuromuscular integrity of both the smooth muscle and the intrinsic en ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: 102

    DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides

    SBC: Initos Pharmaceuticals LLC            Topic: 999

    DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Developing therapeutic inhibitors of CIB1 for breast cancer

    SBC: Reveris Therapeutics            Topic: 102

    DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Malignant primary brain tumors represent the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma Glioblastoma GBM is uniformly lethal and current therapy is non specific and produces a median overall survival of andlt months In contrast immunotherapeutic approaches are exq ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Medical Images HTML and Clinical Trial Remote Collaboration

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Medical drugs and devices are regulated by the U S Food and Drug Administration FDA based on data from multicenter clinical trials In U S spending on clinical trials was approximately $ billion Over the past decade the efficiency of clinical trials has been improved by electronic data capture EDC systems whose use has increased from to ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government